Glioblastoma (GBM) trials

AI-generated summary

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies is being studied. Conditions: Advanced Malignant Solid Neoplasm, RAS Mutation, Lung Cancer +3 • Eligibility: Inclusion Criteria (Key Factors): 1. Has pathologically confirmed advanced or metastatic malignancy characterized by one or more of the following: * Participant is intolerant of existing therapy(ies) known…. Goal: RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard therapy, or have previously failed other therapies. The study has two phases. Phase/Status/Sponsor: Unknown phase; RECRUITING; RasCal Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors is being studied. Conditions: Neoplasms, Brain, Glioblastoma Multiforme, Glioblastoma of Cerebellum +30 • Eligibility: Inclusion Criteria: * Age ≥ 36 months and \< 22 years * Pathologically proven malignant cerebellar brain tumor (including medulloblastoma, glioblastoma multiforme, giant cell glioblastoma, anaplastic astrocytoma, primitive…. Goal: This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell killing, and an anti-tumor immune response, will also be tested. Phase/Status/Sponsor: Unknown phase; RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss is being studied. Conditions: Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme, Glioma, Malignant +4 • Eligibility: Inclusion Criteria: * Has a tumor with a confirmed MTAP loss * Is ≥18 years of age at the time of signature of the main study ICF *…. Goal: This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tumor types with a confirmed MTAP loss. Phase/Status/Sponsor: Unknown phase; RECRUITING; Tango Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works in Patients With Recurrent Glioblastoma is being studied. Conditions: Recurrent Glioblastoma • Eligibility: Inclusion Criteria: * Adults, 18-75 years of age at the time of giving informed consent. Local laws will be followed if the age at consent is older. *…. Goal: This multi-site Phase II study will enroll adults with histologically confirmed diagnosis of World Health Organization (WHO) Grade IV glioblastoma (GBM) consistent with WHO central nervous system (CNS) 2021 criteria who have received prior first-line treatment including with at least radiotherapy and temozolomide, with a Karnofsky performance status (KPS) ≥60, adequate organ function, and at least one measurable lesion according to the response assessment in neuro-oncology (RANO) 2.0 criteria. Phase/Status/Sponsor: Unknown phase; RECRUITING; BioNTech SE.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids is being studied. Conditions: Glioblastoma, Brain Tumor, Cannabis +1 • Eligibility: Inclusion Criteria: * Histological diagnosis of MGMT promoter methylated, IDH wild type (WT) GBM with consistent local molecular pathology (repeat biopsy at recurrence is NOT required). * First…. Goal: ARISTOCRAT is a phase II, multi-centre, double-blind, placebo-controlled, randomised trial to compare the cannabinoid Nabiximols with placebo in patients with recurrent MGMT methylated glioblastoma (GBM) treated with temozolomide (TMZ). Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Birmingham.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Key Longitudinal Associations With Risk and Glioblastoma Outcomes is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: * At least 18 years old * Pathologically-confirmed diagnosis of glioblastoma multiforme (GBM) or grade 4 brain tumor * Participant is accessible for follow-up (has a…. Goal: The goal of this observational study is to find out what factors affect the health and risks in adults with glioblastoma (GBM), a grade 4 brain cancer. The main questions it aims to answer are: * How do genetic and immune system factors impact survival and quality of life in GBM patients? Phase/Status/Sponsor: Unknown phase; RECRUITING; Duke University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma is being studied. Conditions: Progressive Glioblastoma, Recurrent Glioblastoma • Eligibility: Inclusion Criteria: * Histologically-proven glioblastoma (World Health Organization \[WHO\] 2021 criteria) * Progressive or recurrent disease per Response Assessment in Neuro-Oncology (RANO) criteria * No IDH mutation (IDH1…. Goal: This phase II trial compares the safety, side effects and effectiveness of anti-lag-3 (relatlimab) and anti-PD-1 blockade (nivolumab) to standard of care lomustine for the treatment of patients with glioblastoma that has come back after a period of improvement (recurrent). Relatlimab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma is being studied. Conditions: Astrocytoma, IDH-Mutant, Grade 2, Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant, Recurrent Adult Diffuse Midline Glioma, H3 K27-Mutant +4 • Eligibility: Inclusion Criteria: * Patients must have histologically, molecularly, or cytologically confirmed recurrent astrocytic tumors including: * GBM or variants, IDH-wildtype, grade 2-4 (standard curative measures available or not)…. Goal: This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial is being studied. Conditions: Glioblastoma, IDH-Wildtype • Eligibility: Inclusion Criteria: * Patient must be ≥ 18 years of age. * Patient must have a Karnofsky Performance Status ≥ 60%. * Patient must have newly diagnosed GBM…. Goal: This phase II trial studies whether different imaging techniques can provide additional and more accurate information than the usual approach for assessing the activity of tumors in patients with newly diagnosed glioblastoma. The usual approach for this currently is magnetic resonance imaging (MRI). Phase/Status/Sponsor: Unknown phase; RECRUITING; ECOG-ACRIN Cancer Research Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors is being studied. Conditions: Central Nervous System Neoplasms, Atypical Teratoid/Rhabdoid Tumor, Diffuse Midline Glioma, H3 K27M-Mutant +4 • Eligibility: Inclusion Criteria: Screening Eligibility 1. Age ≤ 21 years of age 2. Primary CNS tumor 3. For Cohort A, must have evidence of relapsed or refractory non-brainstem CNS…. Goal: Loc3CAR is a Phase I clinical trial evaluating the use of autologous B7-H3-CAR T cells for participants ≤ 21 years old with primary CNS neoplasms. B7-H3-CAR T cells will be locoregionally administered via a CNS reservoir catheter. Phase/Status/Sponsor: Unknown phase; RECRUITING; St. Jude Children's Research Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial is being studied. Conditions: Glioblastoma, Recurrence Tumor • Eligibility: Inclusion Criteria: * Histologically or cytologically confirmed glioblastoma, according to World Health Organization \[WHO\] 2021 with unequivocal first progression after standard (6 weeks radiotherapy \[RT\]) with concurrent \&…. Goal: This is a multicentric phase II open-label clinical trial aiming to assess the efficacy of the combination of trimipramine and atezolizumab with bevacizumab in patients with recurrent glioblastoma. Eligible patients will be assigned to two cohorts depending on whether there is a medical indication for a neurosurgical resection from first recurrent tumor or not. Phase/Status/Sponsor: Unknown phase; RECRUITING; Centre Hospitalier Universitaire Vaudois.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma is being studied. Conditions: Glioblastoma • Eligibility: Phase 2 Inclusion Criteria: 1. Age ≥ 18 years. 2. Able to understand and provide a signed informed consent that fulfills the relevant IRB or IEC guidelines. 3.…. Goal: This study consists of 2 portions. The phase 2 portion is an open-label, single-arm study to evaluate the safety and efficacy of NAI, PD-L1 t-haNK, and bevacizumab combination therapy in participants with recurrent or progressive GBM. Phase/Status/Sponsor: Unknown phase; RECRUITING; ImmunityBio, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET) Guided in Patients With Partially- or Non-operated Glioblastoma is being studied. Conditions: Glioblastoma Multiforme, Adult • Eligibility: Inclusion Criteria: * Unfit patient without indication to the STUPP protocol : Cohort 1 : Non-operable patients and ≥ 18 years old or ≤ 70 years old and…. Goal: Glioblastoma (GBM) is the most common primary brain cancer in adults. Surgery, chemoradiotherapy (temozolomide TMZ) and then adjuvant TMZ is the standard treatment. Phase/Status/Sponsor: Unknown phase; RECRUITING; Centre Paul Strauss.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma is being studied. Conditions: Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III • Eligibility: Screening Inclusion Criteria for Phase 1 and Phase 2: * Signed written informed consent approved before undertaking any study-specific procedures. * Age ≥18 years of age. * Willing…. Goal: The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of Debio 0123 combined with temozolomide (TMZ) (Arm A) and with TMZ and radiotherapy (RT) (Arms B and C) and to characterize the safety and tolerability of these combinations in adult participants with glioblastoma (GBM). Arm B which was previously added to the protocol, has been permanently halted per the safety monitoring committees' decision on the safety findings of this arm. Phase/Status/Sponsor: Unknown phase; RECRUITING; Debiopharm International SA.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2) is being studied. Conditions: Neoplastic Disease, Glioblastoma, Glioblastoma Multiforme • Eligibility: Inclusion Criteria: 1. Understand and voluntarily sign the informed consent form prior to any study related procedure and/or assessments being conducted. 2. Are Male or Female, and aged…. Goal: This is an open label, single arm, parallel-group, multicentre, and dose finding study to evaluate the safety of ascending radioactive dose levels of 131I-TLX101 administered intravenously in combination with best standard of care in newly diagnosed GBM patients. Phase/Status/Sponsor: Unknown phase; RECRUITING; Telix Pharmaceuticals (Innovations) Pty Limited.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma is being studied. Conditions: Glioblastoma Multiforme • Eligibility: Inclusion Criteria To be eligible to participate in the study, a patient must meet all of the following inclusion criteria: * Patient must have radiographically-confirmed progression of, or…. Goal: This multi-site, Phase 1/2a clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with radiographically-confirmed progression of Grade IV glioma or recurrent primary or secondary Grade IV glioma. The study will have two phases, Phase 1 and Phase 2a. Phase/Status/Sponsor: Unknown phase; RECRUITING; Neonc Technologies, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis is being studied. Conditions: Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult +18 • Eligibility: Inclusion Criteria: * Patient must be ≥ 18yrs of age. * Patient must have the ability to understand, and the willingness to sign, a written informed consent form.…. Goal: This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH- mutant, Glioblastoma IDH-wildtype, and the safety, pharmacokinetics and efficacy of a repeated dose regimen of NEO212 when given with select SOC for the treatment of solid tumor patients with radiographically confirmed uncontrolled metastases to the brain. The study will have three phases, Phase 1, Phase 2a and Phase 2b. Phase/Status/Sponsor: Unknown phase; RECRUITING; Neonc Technologies, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling is being studied. Conditions: Brest Cancer, Lung Cancer (NSCLC), Pancreatic Cancer, Adult +5 • Eligibility: Phase 1 (Common Cancer Early Detection - CCANED) Inclusion Criteria: * Age: Adults aged 40 years or older. * Confirmed diagnosis of one of the following common cancers:…. Goal: The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients. This two-phase, multi-center observational study aims to identify specific transcriptomic biomarkers in platelets and immune cells that distinguish cancer patients from healthy individuals and correlate with treatment outcomes. Phase/Status/Sponsor: Unknown phase; RECRUITING; Javier Toledo.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Feasibility and Efficacy of Dose Timing (Morning vs Evening) of Temozolomide in the Treatment of Glioblastoma is being studied. Conditions: IDH-Wildtype Glioblastoma, Glioblastoma (GBM) • Eligibility: Inclusion Criteria: * 18 years of age or older * Newly diagnosed IDH-wildtype glioblastoma * Completed maximal safe brain tumor resection * Completed post-operative brain RT * Plan…. Goal: The body's biological functions follow a circadian rhythm, meaning that individual biological functions in the body change over a 24-hour cycle. There is evidence suggesting that the body and cancer cells may react differently to anti-cancer treatment based on the time of day they are exposed. Phase/Status/Sponsor: Unknown phase; RECRUITING; Ottawa Hospital Research Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Chemoradiotherapy Versus Chemotherapy for Elderly and Frail GBM Patients is being studied. Conditions: Glioblastoma Multiforme • Eligibility: Inclusion Criteria: 1. Newly-diagnosed, histologically proven, intracranial glioblastoma with maximal safe resection. Biopsy alone is expected if resection is not possible. MGMT promoter methylation status must be tested…. Goal: Currently, the optimal treatment regimen for elderly Glioblastoma (GBM) patients with poor performance status (PS) is unknown. Based on data for elderly GBM patients and the limited data for patients with poor PS, hypofractionated RT or a short course of Temozolomide (TMZ) may provide survival benefit without the added toxicity and inconvenience of a more protracted treatment regimen. Phase/Status/Sponsor: Unknown phase; RECRUITING; AHS Cancer Control Alberta.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Prospective Cohort of Patients With Newly Diagnosed Glioblastoma: Analysis of MMP2 and MMP9 Expression and Correlation to Neuro-imaging Features. is being studied. Conditions: Brain Tumor • Eligibility: Inclusion Criteria: * Patient, male or female, aged 18 years or over * Imaging suggestive of glioblastoma * Patient eligible for excision surgery (partial, subtotal or macroscopically complete)…. Goal: Glioblastoma is the most frequent and aggressive primary brain tumor in adults. A team recently showed that baseline plasma levels of matrix metalloproteinase-2 (MMP2) and matrix metalloproteinase-9 (MMP9) were correlated to bevacizumab activity in patients with recurrent glioblastoma. Phase/Status/Sponsor: Unknown phase; RECRUITING; Assistance Publique Hopitaux De Marseille.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors is being studied. Conditions: Cervical Cancer, Breast Cancer, Colon Cancer +4 • Eligibility: 1. Adult participants (age ≥ 18 years old) with any of the following advanced or metastatic solid tumors (documented history of histologically confirmed diagnosis): 1. Metastatic castration-resistant prostate…. Goal: A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic GRPR-expressing Tumors Phase/Status/Sponsor: Unknown phase; RECRUITING; Orano Med LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This Mayo Clinic-sponsored trial, currently recruiting, tests delivering cancer treatment at home versus in the clinic for adults with advanced cancer who are already receiving standard therapy. It aims to learn how the home-based approach affects patient experiences, preferences, comfort with home infusions, and overall quality of life compared with usual clinic care. The study also looks at safety of home administration with remote monitoring, and outcomes like emergency room visits, hospitalizations, and overall survival. Eligible participants are adults with various cancer types on eligible regimens, but those who need 24/7 assistance with daily activities, are currently inpatient, or have uncontrolled illness may be excluded.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Targeted Pediatric High-Grade Glioma Therapy is being studied. Conditions: High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma +6 • Eligibility: Inclusion Criteria: 1. Age: Patients must be ≥12 months and ≤39 years of age at the time of enrollment onto this screening protocol. 2. Diagnosis: Patients with newly…. Goal: The goal of this study is to perform genetic sequencing on brain tumors from children, adolescents, and young adult patients who have been newly diagnosed with a high-grade glioma. This molecular profiling will decide if patients are eligible to participate in a subsequent treatment-based clinical trial based on the genetic alterations identified in their tumor. Phase/Status/Sponsor: Unknown phase; RECRUITING; Nationwide Children's Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma is being studied. Conditions: Childhood Astrocytoma, Childhood Diffuse Intrinsic Pontine Glioma, Childhood Diffuse Midline Glioma +2 • Eligibility: Inclusion Criteria: * COHORT A and COHORT B: For the dose escalation phase, patients must be ≥ 12 months and \< 18 years of age at the time…. Goal: This phase I clinical trial studies the side effects and best dose of AZD1390 and to see how well it works when given together with radiation therapy for the treatment of pediatric patients with high grade glioma, diffuse midline glioma or diffuse intrinsic pontine glioma. AZD1390 is in a class of medications called kinase inhibitors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Children's Oncology Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry is being studied. Conditions: Cancer, Metastatic, Cancer, Cancer of Pancreas +40 • Eligibility: Inclusion Criteria: * Pts with solid and hematological malignancies; * Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2,…. Goal: International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention. Phase/Status/Sponsor: Unknown phase; RECRUITING; Massive Bio, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors is being studied. Conditions: Melanoma, Medullary Thyroid Cancer, Sinonasal Undifferentiated Carcinoma +8 • Eligibility: Inclusion Criteria: 1. Subject has provided informed consent/assent prior to initiation of any study specific activities/procedures. 2. Subjects ≥ 18 years of age at the time of signing…. Goal: Phase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24 patients with extracranial anatomic radiation sites. I) After lead in of 10 patients demonstrating safety of treatment, allow for expansion to cranial sites of disease (N=6-10) with continued enrollment in main cohort II) If toxicity criteria is not met in concurrent RT tarlatamab cohort, we will continue with sequential RT, either A) delivered within 7 days prior to cycle 1 day 1, or B) delivered during cycle 1 -2 but with pre- and post-RT washout of 7 days with no drug during RT, to examine safety in a temporally spaced setting. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Arizona.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

FearLess in NeuroOncology is being studied. Conditions: Primary Malignant Brain Tumor, Glioblastoma (GBM), Astrocytoma +2 • Eligibility: Inclusion Criteria: Patients: * Self-report a diagnosis of a primary malignant brain tumor (grade II-IV) * \>2 weeks post-cranial resection or biopsy * Elevated Fear of Recurrence Distress…. Goal: The overarching goal of this project is to assess the feasibility, acceptability, and appropriateness of recruitment methods, target population, and a waitlist design to finalize the protocol of FearLess in primary malignant brain tumor patients and caregivers Phase/Status/Sponsor: Unknown phase; RECRUITING; Virginia Commonwealth University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases is being studied. Conditions: Glioblastoma (GBM), Brain Metastasases • Eligibility: Inclusion Criteria: * 1\. Diagnosed with: (a) GBM according to the 2021 WHO criteria, who have progressed on or following standard of care therapy, including maximal safe resection…. Goal: This will be an open-label Phase 0/1 study that will enroll approximately 15 participants, 9 participants with recurrent WHO Grade 4 glioma (rGBM) and 6 participants with brain metastases, who will receive the investigational drug risvutatug rezetecan (GSK5764227), a B7-H3-targeted antibody-drug conjugate (ADC) with the GSK5757810 payload. The trial will consist of a Phase 0 component (subdivided into Arms A and B) and an Expansion Phase 1 component. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Nader Sanai.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Supramarginal Resection in Glioblastoma is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: 1. A suspected diagnosis of supratentorial glioblastoma by MRI.(A) 2. Indication for surgical treatment and where supramarginal resection is considered possible according to the preoperative imaging.…. Goal: Gliomas are the most common malignant brain tumor. Glioblastoma, WHO grade IV astrocytoma, is the most common subtype and unfortunately also the most aggressive subtype with median survival in population based cohorts being only 10 months. Phase/Status/Sponsor: Unknown phase; RECRUITING; St. Olavs Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide is being studied. Conditions: Glioblastoma, IDH-wildtype • Eligibility: Inclusion Criteria: 1. Provision of signed informed consent for selection and treatment phase obtained from the patient/legal representative prior to performing any protocol-related procedures, 2. Patients must be…. Goal: Tailored approaches targeting crucial oncogenes and pathways have shown successful results in a number of cancer types and offer exciting perspective in neuro-oncology. IDH (Isocitrate dehydrogenase) wild-type (IDHwt) glioblastoma (GBM) (10%) present a unique and homogenous energetic metabolism which is specifically dependent on the oxidative phosphorylation (OXPHOS) rather than on the aerobic glycolysis. Phase/Status/Sponsor: Unknown phase; RECRUITING; Hopital Foch.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy is being studied. Conditions: Recurrent Glioblastoma, IDH-Wildtype, Recurrent Astrocytoma, IDH-Mutant, Grade 4, Astrocytoma, Grade IV • Eligibility: Inclusion Criteria: * Participants \>= 18 years * Karnofsky Performance Scale (KPS) \>= 60 * Negative pregnancy test done =\< 7 days prior to registration, for persons of…. Goal: This phase I trial tests the safety, side effects, and best dose of allogenic adipose-derived mesenchymal stem cells (AMSCs) in treating patients with glioblastoma or astrocytoma that has come back (recurrent) who are undergoing brain surgery (craniotomy). Glioblastoma is the most common and most aggressive form of primary and malignant tumor of the brain. Phase/Status/Sponsor: Unknown phase; RECRUITING; Mayo Clinic.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells is being studied. Conditions: Glioblastoma Multiforme, Glycolytic Index, Epidermal Growth Factor Receptor • Eligibility: Inclusion Criteria: * Age \> 18 * Patients with newly diagnosed or recurrent glioblastoma clinically indicated for resective surgery Exclusion Criteria: * Patients who cannot obtain an MRI…. Goal: The purpose of this project is to validate a new combined MRI and PET imaging technique as a biomarker or measure of glycolysis in brain tumors. To accomplish this, the investigators propose obtaining image-guided measures of tissue pH and biopsied tissue in tumor areas selected for bulk resection surgery. Phase/Status/Sponsor: Unknown phase; RECRUITING; Jonsson Comprehensive Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma is being studied. Conditions: Glioblastoma, Recurrent Glioblastoma • Eligibility: Inclusion Criteria: For Cohort A and C (non-surgical): 1. Participants must have histologically or cytologically confirmed 1st, 2nd or 3rd recurrence GBM that has recurred or progressed (per…. Goal: This phase I/Ib trial tests the side effects, best dose, tolerability, and effectiveness of RMC-5552 in treating patients with glioblastoma that has come back (recurrent). RMC-5552 is a type of medicine called an mechanistic target of rapamycin (mTOR) inhibitor. Phase/Status/Sponsor: Unknown phase; RECRUITING; Nicholas Butowski.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma is being studied. Conditions: Glioblastoma, IDH-wildtype, Metformin, Malignancies • Eligibility: Inclusion Criteria: * Patients with newly diagnosed histologically confirmed GBM (WHO grade IV, IDH wild type) undergoing surgical resection; * hypomethylation or hypermethylation of MGMT assessed post-surgery; *…. Goal: About 75% of CNS malignant tumors are classified as gliomas and the IDH-wildtype glioblastoma (GBM) represents the most aggressive form among CNS malignancies. This is a nationwide single-center phase II drug clinical trial with an approximate duration of 32 months. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Milano Bicocca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Loupe-Based Intraoperative Fluorescence Imaging is being studied. Conditions: Glioblastoma Multiforme, Anaplastic Astrocytoma • Eligibility: Inclusion Criteria: * adults with brain malignant gliomas undergoing resection * at least 18 years of age * able to understand the consent Exclusion Criteria: * pregnant women…. Goal: Glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA) are the most common primary malignant brain tumors. Survival of patients with these brain tumors is directly related to the extent of resection. Phase/Status/Sponsor: Unknown phase; RECRUITING; Guoqiang Yu.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 is being studied. Conditions: Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma +11 • Eligibility: Inclusion Criteria: * Frozen biopsy consistent with glioma by neuropathologist at the time of the first surgery in this longitudinal trial. Biopsy confirmation of glioma or infiltrative glioma…. Goal: This research study is evaluating an investigational drug, an oncolytic virus called rQNestin34.5v.2. This research study is a Phase I clinical trial, which tests the safety of an investigational drug and also tries to define the appropriate dose of the investigational drug as a possible treatment for this diagnosis of recurrent or progressive brain tumor. Phase/Status/Sponsor: Unknown phase; RECRUITING; Dana-Farber Cancer Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Prognostic Potential of Olfactory Function in Glioblastoma: a Prospective Observational Study is being studied. Conditions: Glioblastoma Multiforme, Adult, Glioblastoma or Gliosarcoma, Glioblastoma, Adult • Eligibility: Inclusion Criteria: * At least 18 years of age * Newly-diagnosed glioblastoma (IDH wild-type) * Never received prior chemotherapy * Never received radiotherapy to the head or neck…. Goal: The study aims to investigate the prognostic significance of olfactory function in patients with glioblastoma. We are examining olfactory function at various points during therapy and correlating the results with survival data. Phase/Status/Sponsor: Unknown phase; RECRUITING; Sied Kebir.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors is being studied. Conditions: Solid Tumors, Advanced Cancer, Renal Cancer +15 • Eligibility: Major Inclusion Criteria: 1. Men and women 18 years of age or older. 2. 9 cohorts will be enrolled: * Cohort A1 / Exon 14 NSCLC MET inhibitor…. Goal: To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring wild-type MET with overexpression of HGF and MET * efficacy of APL-101 as an add-on therapy to EGFR inhibitor for the treatment of NSCLC harboring EGFR activating mutations and developed acquired resistance with MET amplification and disease progression after documented CR or PR with 1st line EGFR inhibitors (EGFR-I) Phase/Status/Sponsor: Unknown phase; RECRUITING; Apollomics Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Clinical Trial of BMS-986504 in Recurrent GBM Patients is being studied. Conditions: Glioblastoma WHO Grade IV • Eligibility: Inclusion Criteria: * Participants with the diagnosis of glioblastoma by the 2021 WHO criteria, who have progressed on or following previous tumor-directed therapy, which must have included a…. Goal: This is an open-label, multi-center, Phase 0/1 dose-escalation trial designed to enroll up to 9 total recurrent glioblastoma (rGBM) participants with confirmed MTAP loss/deletion in their archival or pretreatment biopsy tissue, who are scheduled for surgical resection. MTAP loss/deletion will be determined by next-generation sequencing (NGS). Phase/Status/Sponsor: Unknown phase; RECRUITING; Nader Sanai.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Glutamate Excitotoxicity and Its Role in Glioblastoma Biology is being studied. Conditions: Brain Tumor, Primary • Eligibility: Inclusion Criteria: * Adult patients with a brain lesion suspected for GBM, candidate to gross total tumor resection (GTR), followed by radiotherapy and chemotherapy (concomitant and adjuvant). *…. Goal: Gliomas are the most frequent type of primary brain tumors in adults; among them glioblastoma multiforme (GBM) is the most malignant, being associated with the worst prognosis. Glutamate (Glu) is an aminoacid, responsible for essential functions in the Central Nervous System (CNS), acting both as metabolite and neurotransmitter. Phase/Status/Sponsor: Unknown phase; RECRUITING; IRCCS San Raffaele.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA is being studied. Conditions: Glioblastoma Multiforme, Anaplastic Astrocytoma • Eligibility: Inclusion Criteria: * 18 years of age or older. * Patients with a documented histologic diagnosis of relapsed or refractory glioblastoma multiforme (GBM), anaplastic astrocytoma (AA) or anaplastic…. Goal: The high-grade malignant brain tumors, glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), comprise the majority of all primary brain tumors in adults. This group of tumors also exhibits the most aggressive behavior, resulting in median overall survival durations of only 9-12 months for GBM, and 3-4 years for AA. Phase/Status/Sponsor: Unknown phase; RECRUITING; Northwell Health.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138) is being studied. Conditions: Glioma, Glioblastoma, Brain Tumor • Eligibility: Inclusion Criteria: 1. Patients with radiographic evidence of suggestive of a primary high-grade glioma 2. Brain MRI with contrast demonstrates an enhancing mass within 60 days prior to…. Goal: The purpose of this study is to evaluate the treatment regimen of using Laser Interstitial Thermal Therapy (LITT) and Hypo-fractionated Radiation Therapy to treat patients with newly diagnosed gliomas. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Maryland, Baltimore.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of LP-184 in Patients With Advanced Solid Tumors is being studied. Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, GBM +4 • Eligibility: Patient Inclusion Criteria: 1. ≥18 years of age at the time of consent 2. Provided signed written ICF and voluntary consent prior to any mandatory study-specific procedures, sampling,…. Goal: The primary objective of this study is to evaluate the safety, tolerability, MTD and RP2D of LP-184 in patients with advanced solid tumors who have relapsed from or are refractory to standard therapy or for whom no standard therapy is available. The secondary objectives are to characterize the PK of LP-184 and its metabolites in plasma and assess clinical activity of LP-184. Phase/Status/Sponsor: Unknown phase; RECRUITING; Lantern Pharma Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma is being studied. Conditions: Glioblastoma Multiforme • Eligibility: Inclusion Criteria: * Newly-diagnosed adults with WHO (World Health Organization) Grade IV Glioblastoma or gliosarcoma based on histopathological or molecular criteria who had carmustine wafers placed at resection…. Goal: The purpose of the study is to evaluate the safety and survival of carmustine wafers and radiation and retifanlimab with or without temozolomide (TMZ) in newly-diagnosed adult subjects with glioblastoma multiform after carmustine wafer placement. Phase/Status/Sponsor: Unknown phase; RECRUITING; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) is being studied. Conditions: Glioblastoma Multiforme, Glioblastoma Multiforme, Adult, Supratentorial Glioblastoma +1 • Eligibility: Inclusion Criteria: * Patients with histologically confirmed, newly diagnosed, supratentorial glioblastoma or gliosarcoma who have undergone gross total tumor resection or near gross total resection (resection of \>85%…. Goal: This phase II trial studies the effect of P140K MGMT hematopoietic stem cells, O6-benzylguanine, temozolomide, and carmustine in treating participants with supratentorial glioblastoma or gliosarcoma who have recently had surgery to remove most or all of the brain tumor (resected). Chemotherapy drugs, such as 6-benzylguanine, temozolomide, and carmustine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing. Phase/Status/Sponsor: Unknown phase; RECRUITING; Leland Metheny.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Drug Response Testing and Repurposing Using Glioblastoma Organoid is being studied. Conditions: Glioblastoma, Organoid • Eligibility: Inclusion Criteria: * primary or recurrent glioblastoma * patients treated with standard treatment including surgery and temozolomide based chemoradiation therapy * sufficient tumor sample is available for organoid…. Goal: The aim of this observational study, based on a prospectively collected cohort, is to evaluate the prognostic value of patient-derived organoids in predicting responses to conventional and repurposing drugs, including temozolomide, in patients with primary or recurrent glioblastoma. The primary question is whether the patient's response to temozolomide is recapitulated in their corresponding patient-derived glioblastoma organoid (GBO). Phase/Status/Sponsor: Unknown phase; RECRUITING; Chungnam National University Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM is being studied. Conditions: Glioblastoma, Anaplastic Astrocytoma • Eligibility: Inclusion Criteria: * All patients must have frozen section biopsy proven anaplastic astrocytoma or glioblastoma multiforme without evidence of multifocal disease defined as multiple lesions greater than 2…. Goal: Study to assess the safety and efficacy of HSV-tk (gene therapy), valacyclovir, radiotherapy and chemotherapy in newly diagnosed glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA). Phase/Status/Sponsor: Unknown phase; RECRUITING; The Methodist Hospital Research Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients is being studied. Conditions: Glioblastoma Multiforme, Glioblastoma, Glioblastoma Multiforme, Adult +5 • Eligibility: Inclusion Criteria: 1. Male or female patients ≥ 18 years of age at the time of study enrollment. 2. Body mass index (BMI) ≥ 17 kg/m2. 3. Patients…. Goal: This will be a prospective, randomized, standard of care (SoC) controlled, parallel, open-label, multicenter pivotal study to investigate the efficacy and safety of Bevacizumab (BEV) in combination with or without microbubble (MB)-mediated FUS in patients with recurrent GBM. BEV represents the physician's best choice for the standard of care in rGBM after previous treatment with surgery (if appropriate), standard radiotherapy with temozolomide chemotherapy, and with adjuvant temozolomide. Phase/Status/Sponsor: Unknown phase; RECRUITING; NaviFUS Corporation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Treatment Intensification With Temozolomide in Adults With a Glioblastoma is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: * Patient ≥18 years old * Histological diagnosis of de novo GBM (extemporaneous diagnosis or standard pathological examination). In case of extemporaneous diagnosis, the patient can…. Goal: Due to conflicting data on the optimal moment to start TMZ chemotherapy and the impact of prolongation of the adjuvant phase with TMZ, the ANOCEF (Association des Neuro-Oncologues d'Expression Francophone) group proposes this randomized trial comparing an intensified arm (early TMZ and extended adjuvant TMZ until toxicity, progression or patient refusal) versus the classical EORTC regimen as control (RT and concomitant TMZ started 4-6 weeks after surgery followed by a number of adjuvant TMZ cycles strictly limited to 6) for primary GBM adult patients. Phase/Status/Sponsor: Unknown phase; RECRUITING; Centre Oscar Lambret.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Allogeneic γδT Cells in Glioblastoma is being studied. Conditions: Glioblastoma (GBM), Glioblastoma Multiforme (GBM) • Eligibility: Inclusion Criteria: 1. Male or female, age 18-70 years old (both ends included) 2. At least one evaluable lesion with previous biopsy or pathohistologic confirmation of glioblastoma (WHO…. Goal: This first-in-human clinical study aims to evaluate the safety and feasibility of locally delivered, allogeneic γδ T cells (genetically edited with ARIH1 and BCL11b knockout, designated ABOUT γδT cells) in patients with glioblastoma multiforme (GBM). The engineered effector cells are delivered via localized administration to selectively target and eliminate residual GBM cells. Phase/Status/Sponsor: Unknown phase; RECRUITING; Peking University Third Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

IA Carboplatin + Radiotherapy in Relapsing GBM is being studied. Conditions: Glioblastoma Multiforme, Relapse • Eligibility: Inclusion Criteria: 1. Histological diagnosis of glioblastoma multiforme 2. Radiological progression on an MRI scan, according to the RANO criteria, in the context of a known glioblastoma multiforme,…. Goal: Treatment of glioblastoma involves an optimal surgery, followed by a combination of radiation and temozolomide chemotherapy. Progression-free survival (PFS) with this treatment is only 6.9 months and relapse is the norm. Phase/Status/Sponsor: Unknown phase; RECRUITING; Université de Sherbrooke.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Intraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblastoma is being studied. Conditions: Glioblastoma Multiforme, Relapse • Eligibility: Inclusion Criteria: 1. Histological diagnosis of glioblastoma multiforme. 2. Radiological progression on an MRI scan, according to the RANO criteria, in the context of a known glioblastoma multiforme,…. Goal: The standard of care for glioblastoma (GBM) treatment involves maximal resection followed by concomitant radiotherapy and temozolomide. Progression-free survival (PFS) with this treatment is only 6.9 months and relapse is inevitable. Phase/Status/Sponsor: Unknown phase; RECRUITING; Université de Sherbrooke.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM is being studied. Conditions: Glioblastoma • Eligibility: I. Inclusion Criteria: Participants must meet the following criteria on screening examination to be eligible to participate in the study (labs/tests/assessments within 14 days prior to initial study…. Goal: This research study is studying a new type of vaccine as a possible treatment for patients with glioblastoma. This research study is a Phase I clinical trial, which tests the safety of an investigational intervention and also tries to define the appropriate dose of the intervention to use for further studies. Phase/Status/Sponsor: Unknown phase; RECRUITING; Dana-Farber Cancer Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM is being studied. Conditions: Recurrent Glioblastoma, Refractory Glioblastoma • Eligibility: Inclusion Criteria Informed Consent and Willingness to Participate * 1\. Documented informed consent of the participant and/or legally authorized representative. Assent, when appropriate, will be obtained per institutional…. Goal: This phase I trial studies the side effects and how well IL13Ralpha2-CAR T cells work when given alone or together with nivolumab and ipilimumab in treating patients with glioblastoma that has come back (recurrent) or does not respond to treatment (refractory). Biological therapies, such as IL13Ralpha2-CAR T cells, use substances made from living organisms that may attack specific glioma cells and stop them from growing or kill them. Phase/Status/Sponsor: Unknown phase; RECRUITING; City of Hope Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma is being studied. Conditions: Recurrent Astrocytoma, IDH-Mutant, Grade 3, Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma • Eligibility: Inclusion Criteria: * Documented informed consent of the participant and/or legally authorized representative * Note: For research participants who do not speak English, a short form consent may…. Goal: This phase I trial tests the safety, side effects and best dose of TGFβR2KO/IL13Rα2 chimeric antigen receptor (CAR) T-cells given within the skull (intracranial) in treating patients with glioblastoma or IDH-mutant grade 3 or 4 astrocytoma that has come back after a period of improvement (recurrent) or that is growing, spreading, or getting worse (progressive). CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack tumor cells. Phase/Status/Sponsor: Unknown phase; RECRUITING; City of Hope Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma is being studied. Conditions: Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme +4 • Eligibility: Inclusion Criteria: * Diagnosis of World Health Organization (WHO) G4 classified GBM, IDH-wildtype (patients with GBM) or G3 astrocytoma (IDH1 or 2 mutant; CDKN2A/B intact) per WHO 2021…. Goal: The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma or astrocytoma is newly diagnosed, and to evaluate safety and tolerability of this combination at that dose. Phase/Status/Sponsor: Unknown phase; RECRUITING; Orbus Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Hitting the Mark: Introducing State-of-the-art MRI for Precision Radiotherapy of Glioblastoma is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: * Written informed consent; * Adult (18 years or older); * Diagnosed with IDH-wildtype glioblastoma, as confirmed by pathology including molecular analysis post resection/biopsy; * Referred…. Goal: The goal of this prospective cohort study is to assess the potential of advanced MRI for improved radiotherapy target delineation in patients diagnosed with glioblastoma. The main questions it aims to answer are: * How does the coverage of the recurrence volume by a radiotherapy plan based on advanced MRI compare to the coverage by the clinical radiotherapy plan? Phase/Status/Sponsor: Unknown phase; RECRUITING; Erasmus Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

UNIty-Based MR-Linac Guided Adaptive RadioThErapy for High GraDe Glioma-3 (UNITED-3) is being studied. Conditions: Glioblastoma Multiforme, Adult • Eligibility: Inclusion Criteria: * Histopathologically confirmed, based on biopsy or surgical resection, glioblastoma, or grade 4 astrocytoma, as defined by the World Health Organization (WHO) * Deemed clinically appropriate…. Goal: The goal of this study is to test whether an adaptive radiation therapy (RT), two-phase approach in participants with glioblastoma impacts local control compared to standard non-adaptive RT approach. The main questions of the study are to see how this adaptive, two-phase RT approach compares to standard RT in terms of: * Local control * Overall and progression-free survival * Patterns of failure * Toxicity, Neurological Function, and Quality of Life Phase/Status/Sponsor: Unknown phase; RECRUITING; Sunnybrook Health Sciences Centre.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM) is being studied. Conditions: Glioblastoma Multiforme • Eligibility: Inclusion Criteria: 1. Adult males and females aged over 19 years or older at the time of Informed Consent. 2. Diagnosed with GBM according to the World Health…. Goal: This is a Phase 1 study to evaluate the maximum tolerated dose, safety and efficacy of BEY1107 in combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM) Phase/Status/Sponsor: Unknown phase; RECRUITING; BeyondBio Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP) is being studied. Conditions: Glioblastoma, Glioblastoma, WHO Grade IV • Eligibility: Inclusion Criteria: * Histologic confirmation of glioblastoma, WHO Grade IV (GBM variants are allowed; Lower grade gliomas that have been transformed to GBM will be considered newly diagnosed…. Goal: Glioblastoma multiforme (GBM) is the most common and deadliest primary malignant neoplasm of the central nervous system in adults. Despite an aggressive multimodality treatment approach including surgery, radiation therapy and chemotherapy, overall survival remains poor. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; University of Florida.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM is being studied. Conditions: Glioblastoma Multiforme, Astrocytoma, Grade III • Eligibility: Inclusion Criteria: * All patients must have biopsy proven recurrent anaplastic astrocytoma or glioblastoma multiforme without evidence of multifocal tumor or brainstem involvement. Multifocal disease does not exist…. Goal: Study to assess the safety and efficacy of HSV-tk (gene therapy), valacyclovir, radiotherapy and chemotherapy in recurrent glioblastoma multiforme. Phase/Status/Sponsor: Unknown phase; RECRUITING; David Baskin MD.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Evaluate the Efficacy and Safety of ADCV01 As an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients is being studied. Conditions: GBM • Eligibility: Inclusion Criteria: Stage I (Pre-screening) 1. Patients are ≥ 20 and ≤ 75 years of age at brain tumor resection surgery. 2. Patients with newly diagnosed single, primary,…. Goal: This study is designed with open-label and randomized parallel group to evaluate the efficacy and safety of autologous dendritic cell vaccination (ADCV01) as an add-on treatment for primary glioblastoma multiforme Phase/Status/Sponsor: Unknown phase; RECRUITING; Ever Supreme Bio Technology Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Treatment of Recurrent High-Grade Glioma is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: * Age ≥ 18 years * Histological confirmation of one of the following: * Glioblastoma, IDH-wildtype * Grade 3 or 4 IDH1/2 mutant astrocytoma (2021 WHO…. Goal: The purpose of this study is to test WSD0628 in combination with radiation therapy for recurrent brain tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Mayo Clinic.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma is being studied. Conditions: Recurrent Glioblastoma • Eligibility: Inclusion Criteria: A. Recurrent glioblastoma (or variants such as gliosarcoma) based on one of the following criteria: 1. An area of MRI enhancement consistent with glioblastoma outside of…. Goal: The purpose of this research is to find hidden cancer with an experimental magnetic resonance imaging (MRI) scan called spectroscopic magnetic resonance imaging (sMRI). That spectroscopic MRI scan will be used to increase the area of the brain receiving radiation and then the dose of radiation in attempt to kill more of the cancer. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Miami.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Clinical Evaluation of [68Ga]Ga-XT771 PET for Diagnosis in Patients With Glioblastoma and Clear Cell Renal Cell Carcinoma is being studied. Conditions: Clear Cell Renal Cell Carcinoma and Glioblastoma • Eligibility: Inclusion Criteria: * 1\. signed the informed consent 2. ≥18 years old 3. Patients with glioblastoma or clear cell renal cell carcinoma Exclusion Criteria: * 1\. Known allergy…. Goal: A prospective, open-label, phase 1 study. This clinical trial aims to evaluate the diagnostic value of 68Ga-XT771, a CAIX/CAXII protein-specific probe, in PET/CT imaging for patients with clear cell renal cell carcinoma and glioblastoma. Phase/Status/Sponsor: Unknown phase; RECRUITING; Chinese PLA General Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Anterior Temporal Lobectomy in Temporal Glioblastoma is being studied. Conditions: Newly-diagnosed Glioblastoma, Temporal Lobe • Eligibility: * Suspected glioblastoma with contrast-enhancement in preoperative MRI * Diffuse high-grade glioma in frozen section procedure, newly-diagnosed * Tumor localization (in gadolinium-enhanced MRI): solely temporal, non-dominant side (right…. Goal: The ATLAS/NOA-29 trial is a prospective, multicenter, phase III randomized controlled study evaluating whether anterior temporal lobectomy (ATL), a standardized resection technique adapted from epilepsy surgery, improves clinical outcomes in patients with newly diagnosed glioblastoma of the anterior temporal lobe compared to conventional gross-total resection (GTR). The rationale is based on the concept of glioblastoma as a diffusely connected tumor network, with infiltrative spread extending beyond MRI-detectable tumor margins. Phase/Status/Sponsor: Unknown phase; RECRUITING; University Hospital, Bonn.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pilot Trial for Treatment of Recurrent Glioblastoma is being studied. Conditions: Glioblastoma, Recurrent Disease, Recurrent Glioblastoma • Eligibility: Inclusion Criteria: 1. Study participant has provided informed consent prior to initiation of any study specific activities/procedures. 2. Adult participants, male and female, aged ≥18 who have a…. Goal: This will be a single-arm open-label prospective pilot feasibility trial recruiting 10 adult patients with recurrent glioblastoma who are assigned to receive the personalized study treatment based on the genetic profile of their recurrent GBM tumor resected at the time of surgery. It will be aimed to gather preliminary information on the study intervention and the feasibility of conducting a full-scale trial. Phase/Status/Sponsor: Unknown phase; RECRUITING; AHS Cancer Control Alberta.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests olaparib, a drug that may slow tumor growth, in adults with glioma, cholangiocarcinoma, or other solid tumors that have IDH1 or IDH2 mutations and have progressed after standard treatment. - Participants are grouped into three cohorts: glioma, cholangiocarcinoma, and other IDH-mutant solid tumors, to see how they respond to olaparib. - The study aims to learn the overall response rate, how long patients live without the disease getting worse, overall survival, duration of responses, and the safety of olaparib alone. - Researchers will measure blood and tumor markers, including a molecule called 2HG, to see if these relate to treatment response. - Key exclusions include active uncontrolled brain metastases, prior PARP inhibitor therapy, pregnancy, HIV infection on antiretroviral therapy, and other serious medical conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Irinotecan-ChemoSeed in Surgically Resectable Glioblastoma is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: * 1\. Radiologically relapsed, neuropathologically verified GBM (by the WHO 2021 criteria) (Part 1) or newly diagnosed, radiologically suspected GBM (Part 2) amenable to surgical resection.…. Goal: Part 1 (dose escalation, safety, and preliminary efficacy) Part 1 is a non-randomised, single-arm design in 12 participants with recurrent GBM suitable for maximal safe surgical resection. Part 1 will evaluate safety, determine the MTD of irinotecan-ChemoSeed and the RP2D (corresponding to coverage of as much of the resection cavity as possible, up to the MTD) and evaluate efficacy. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; CRISM Therapeutics LTD.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN). is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: 1. histologically confirmed secondary glioblastoma,or glioblastoma with IDH mutantation 2. Must have evidence of PRPRZ1-MET fusion gene positivity from the result of molecular pre-screening evaluations 3.…. Goal: The goal of this clinical trial is to evaluate the safety and efficacy of PLB1001 Enteric Capsules in the treatment of PTPRZ1-MET fusion gene positive recurrent secondary glioblastoma. The main questions it aims to answer are: 1. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Beijing Pearl Biotechnology Limited Liability Company.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Extensive Resection of Malignant Brain Tumors Using Advanced Imaging Techniques is being studied. Conditions: Glioblastoma, Astrocytoma, IDH-Mutant, Grade 4 • Eligibility: Inclusion Criteria: * Age ≥ 18 years * New clinical and radiological suspected diagnosis of IDH-wildtype glioblastoma or grade IV IDH-mutant astrocytoma * Visible FET PET uptake in…. Goal: Rationale: Patients with IDH-wildtype glioblastoma or grade IV IDH-mutant astrocytoma have a very poor prognosis despite standard treatment consisting of surgery, radiotherapy, and chemotherapy. Diffuse infiltration of the brain by the tumor is thought to be one of the main causes of this therapy-resistance. Phase/Status/Sponsor: Unknown phase; RECRUITING; Amsterdam UMC, location VUmc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: * The subject is at least 18 years of age * The subject has the ability to understand the purposes and risks of the study and…. Goal: This study is designed as a single center, prospective, open label, single-arm therapeutic trial with both surgical and non-surgical cohorts. Phase/Status/Sponsor: Unknown phase; RECRUITING; The University of Texas Health Science Center at San Antonio.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of BL-B01D1 in Patients With Recurrent Glioblastoma is being studied. Conditions: Recurrent Glioblastoma • Eligibility: Inclusion Criteria: 1. Sign the informed consent form voluntarily and follow the protocol requirements; 2. Gender is not limited; 3. Age: ≥18 years old; 4. Recurrent glioblastoma confirmed…. Goal: This is an open-label, multicenter, phase II study to evaluate the safety, efficacy, and pharmacokinetic characteristics of BL-B01D1 for Injection in patients with recurrent glioblastoma. Phase/Status/Sponsor: Unknown phase; RECRUITING; Sichuan Baili Pharmaceutical Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients is being studied. Conditions: Glioblastoma, Glioma, Glioblastoma Multiforme +1 • Eligibility: Inclusion Criteria: 1a. Arm C only: Participants undergoing resection for a suspected newly diagnosed WHO Grade 4 glioma. Participants will also need to have radiation planned as part…. Goal: This is an open-label, single-center Phase 0/1b study that will enroll at least 27 participants with recurrent WHO Grade 4 Glioma requiring re-radiation and approximately 35 participants with newly-diagnosed WHO Grade 4 glioma (nGBM). The trial will be composed of a Phase 0 component (subdivided into Arms A - C), and an expansion Phase 1b. Phase/Status/Sponsor: Unknown phase; RECRUITING; Nader Sanai.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

AB154 Combined With AB122 for Recurrent Glioblastoma is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: 1. Grade IV glioma (glioblastoma and its variants according to the World Health Organization 2021), confirmed in tissue at time of initial diagnosis. Tumors with an…. Goal: This is a phase 0/I exploratory study. Patients at first or second recurrence of glioblastoma will be enrolled. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Yale University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients is being studied. Conditions: Glioblastoma Multiforme • Eligibility: Inclusion Criteria: 1. Patients aged 18 years or older 2. Patients with newly diagnosed glioblastoma, IDH 1 wt, WHO grade IV 3. Radical resection 4. Concomitant treatment with…. Goal: This study is a multicenter randomized double-blinded controlled phase 2 study evaluating the efficacy and safety of the anti-CMV drug valganciclovir vs placebo as add-on therapy in patients with glioblastoma. Valganciclovir is approved for treatment of cytomegalovirus (CMV) infections, but may also have anti-tumoral effects. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Cecilia Soderberg-Naucler.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme is being studied. Conditions: Glioblastoma Multiforme • Eligibility: Inclusion Criteria: * Patient must have newly diagnosed, histologically confirmed GBM. * Patient must have undergone gross total resection, subtotal resection, or biopsy with the extent of resection…. Goal: In this study patients will be treated with 6 weeks of radiation therapy plus temozolomide chemotherapy according to the standard of care. However, the radiation treatment plan will be modified to deliver an higher than routine radiation dose to the subventricular zone which is an area of the brain that contains stem cells that some scientists believe may contribute to glioblastoma recurrence. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype is being studied. Conditions: Glioma, Glioblastoma, High Grade Glioma +2 • Eligibility: * INCLUSION CRITERIA: * Patients must have recurrent diffuse glioma (histologically confirmed by National Institutes of Health (NIH) Laboratory of Pathology) with isocitrate dehydrogenase 1 (IDH1) or isocitrate…. Goal: Background: Gliomas are the most common malignant brain tumors. Some have certain changes (mutations) in the genes isocitrate dehydrogenase 1 (IDH1) or isocitrate dehydrogenase 2 (IDH2). Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma. is being studied. Conditions: Glioblastoma • Eligibility: 1. Subjects must have signed and dated an approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of…. Goal: Phase I/II clinical trial on the per-operative intra-tumoral administration of myeloid dendritic cells plus ipilimumab and nivolumab, followed by repeated intracavitary administration of ipilimumab and nivolumab plus intravenous administration of nivolumab in patients with recurrent glioblastoma. The aim of this clinical trial is to exploit the potential synergy of combined intra-tumoral CTLA-4 and autologous CD1c(BDCA-1)+/CD141(BDCA-3)+ myDC and systemic PD-1 blockade while minimizing the risk for increased immune-related toxicity by intratumoral administration of the CTLA-blocking mAb ipilimumab following the resection of the recurrent glioblastoma. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Universitair Ziekenhuis Brussel.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Radiodynamic Therapy (RDT) With Gliolan in Patients With First Recurrence of Brain Tumor is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: * Written patient consent after comprehensive information * Age \>/= 18 years * Recurrence of supratentorial glioblastoma after initial resection and adjuvant therapy (e.g. radio-chemotherapy, targeted…. Goal: The investigational drug 5-ALA (known under the trade name Gliolan®) is an approved drug for the surgical removal of malignant glioma (WHO grade III and IV). In this trial, the drug is being tested outside of its actual approval as a radiosensitizer in combination with conventional radiotherapy for first-time recurrence (relapse) of malignant glioma. Phase/Status/Sponsor: Unknown phase; RECRUITING; Universität Münster.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Recombinant Human Endostatin Combined with Temozolomide and Irinotecan in Recurrent Gliomas is being studied. Conditions: Glioblastoma, Recurrent, Lower Grade Glioma, Recurrent • Eligibility: Inclusion Criteria: 1. Age ≥ 18 and ≤70; 2. Histopathologically-confirmed, supratentorial GBM or lower-grade gliomas (such as oligodendroglioma, astrocytoma, oligoastrocytoma, anaplastic astrocytoma, anaplastic oligodendroglioma or anaplastic oligoastrocytoma); 3.…. Goal: Almost all gliomas relapse. After temozolomide rechallenge or combination with irinotecan, the progression-free survival rate at 6 months (PFS-6%) of recurrent glioblastoma was about 21%. Phase/Status/Sponsor: Unknown phase; RECRUITING; Beijing Sanbo Brain Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow is being studied. Conditions: Diffuse Glioma, Glioblastoma, Adaptive Radiotherapy +1 • Eligibility: Inclusion Criteria: * Histological diagnosis of diffuse glioma. Patients with IDH-negative GBM (stratum A) and IDH-mutant glioma (astrocytoma or oligodendroglioma) need radiotherapy (stratum B). Age: 18-70 years. Karnofsky…. Goal: Gliomas are common primary brain tumors in adults. Gliomas can be classified into different types based on tumor grade, histopathological features, and molecular characteristics. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Tata Memorial Centre.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

CSF Proteomic Characterization of Glioblastomas is being studied. Conditions: Glioblastoma, Glioblastoma WHO Grade IV, Glioblastoma (GBM) +2 • Eligibility: Inclusion Criteria: * Patients with confirmed diagnosis of glioblastoma (histopathological and molecular). * Patients who voluntarily accept participation in this study. * Patients aged 18 or older. Exclusion…. Goal: The goal of this observational study is to identify proteins that can be found in the cerebrospinal fluid (CSF) of patients with grade IV brain tumors, specifically glioblastomas, and correlate these proteins with progression free survival, overall survival and performance status (functionality). All participants with high probability of glioblastoma will initially be included, final inclusion will be dependent on the definitive histopathological diagnosis of the tumor. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Univeridad Autonoma de Guadalajara.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Natural Progesterone for the Treatment of Recurrent Glioblastoma is being studied. Conditions: Gliosarcoma, Recurrent Glioblastoma • Eligibility: Inclusion Criteria: * Patients must have pathologic confirmation of a glioblastoma or gliosarcoma diagnosis at initial surgery or second or later surgery * Patients may have had up…. Goal: This early phase I trial identifies the best dose, possible benefits and/or side effects of natural progesterone in treating patients with glioblastoma that has come back (recurrent). Progesterone is a type of hormone made by the body that plays a role in the menstrual cycle and pregnancy. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Emory University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas is being studied. Conditions: Glioblastoma, IDH1 Gene Mutation, IDH2 Gene Mutation +7 • Eligibility: Inclusion Criteria: * Arm A Only: Participants must have histologically confirmed World Health Organization (WHO) grade III-IV newly diagnosed IDH1/2-mutant glioma. * Arm B Only: WHO grades I-IV…. Goal: This phase I trial studies the side effects and best dose of BGB-290 and temozolomide in treating adolescents and young adults with IDH1/2-mutant grade I-IV glioma that is newly diagnosed or has come back. BGB-290 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; University of California, San Francisco.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme is being studied. Conditions: Glioblastoma, Gliosarcoma • Eligibility: Inclusion Criteria: * Histologic documentation: newly diagnosed World Health Organization (WHO) grade IV intracranial glioblastoma or gliosarcoma; GBM with oligodendroglial features are NOT PERMITTED in this study if…. Goal: This randomized phase II/III trial studies how well temozolomide and veliparib work compared to temozolomide alone in treating patients with newly diagnosed glioblastoma multiforme. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM is being studied. Conditions: Glioma, Malignant • Eligibility: Inclusion Criteria 1. Age ≥ 18 years of age 2. Newly diagnosed Isocitrate dehydrogenase (IDH) wild type (CARIS result), MGMT promoter unmethylated (CARIS result) WHO grade IV glioma…. Goal: This is a phase 1b study of P30-linked EphA2, CMV pp65, and survivin vaccination (collectively called the P30-EPS vaccine) in HLA-A\*0201 positive patients with a newly diagnosed, unmethylated, and untreated World Health Organization (WHO) grade IV malignant glioma. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Mustafa Khasraw, MBChB, MD, FRCP, FRACP.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas is being studied. Conditions: Newly Diagnosed H3-mutated Glioma • Eligibility: Inclusion Criteria: * Patients present with histologically confirmed diagnosis of an H3.1K27M or H3.3K27M-mutated diffuse midline glioma WHO grade IV (with or without measurable residual tumor after tumor…. Goal: The study "A MultIceNTER Phase I Peptide VaCcine Trial to Exploit NeoePitope-Specific T Cells for the Treatment of H3K27M-Mutated Gliomas - (INTERCEPT H3)" is a non-controlled, open-label, single arm, multicenter phase I trial involving patients with gliomas carrying an H3.1K27M or H3.3K27M mutation. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; German Cancer Research Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM is being studied. Conditions: Glioblastoma Multiforme • Eligibility: Inclusion Criteria: 1. Patients must provide written informed consent prior to any screening procedures. 2. Age 18 years or older. 3. Willing and able to comply with scheduled…. Goal: This phase I trial studies the side effects of stereotactic radiosurgery with MBG453 and spartalizumab in treating patients with recurrent glioblastoma multiforme (GBM). Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor to more precisely target the cancer. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

GammaTile and Stupp in Newly Diagnosed GBM is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: 1. All patients must be ≥ 18 years of age 2. Histopathological and molecular confirmation of newly diagnosed GBM using IDH mutation testing (such as immunohistochemistry…. Goal: In summary, standard of care postoperative chemoradiation for patients with newly diagnosed GBM does not routinely provide durable local control or prolonged overall survival. As discussed above it seems unlikely that patient outcomes will be significantly improved with radiation dose escalation given at the time of the EBRT boost. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; GT Medical Technologies, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma is being studied. Conditions: Medulloblastoma, Glioblastoma Multiforme, Anaplastic Astrocytoma +5 • Eligibility: Screening Inclusion Criteria: * • DIAGNOSIS: Patients with a histologically confirmed diagnosis of a primary CNS tumor that is progressive or recurrent defined as radiographic progression in any…. Goal: Patients will receive a vaccine called SurVaxM on this study. While vaccines are usually thought of as ways to prevent diseases, vaccines can also be used to treat cancer. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Pediatric Brain Tumor Consortium.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glioblastoma is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: * Male or female ≥ 18 years of age * Documentation of a newly diagnosed World Health Organization (WHO) grade IV glioblastoma as evidenced by clinical…. Goal: This phase III trial compares pH weighted chemical exchange saturation transfer (CEST) magnetic resonance imaging (MRI)-based surgical resections to standard of care surgical resections for the treatment of patients with glioblastoma. Standard of care therapy for glioblastoma is surgery to remove tumor tissue that enhances on standard MRI imaging, however, it has been shown that significant tumor burden exists in the region around the tumor tissue that does not enhance with standard MRI. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Jonsson Comprehensive Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Niraparib/TTFields in GBM is being studied. Conditions: Glioblastoma, Recurrent Glioblastoma, GBM • Eligibility: Inclusion Criteria: * Histopathologically or molecularly (per c-IMPACT NOW criteria) proven diagnosis of glioblastoma which is recurrent following radiation therapy (prior dose must have been between 40 and…. Goal: Evaluating the efficacy and safety of niraparib and Tumor-Treating Fields (TTFields) in recurrent glioblastoma (GBM). Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Abramson Cancer Center at Penn Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM is being studied. Conditions: Glioblastoma Multiforme • Eligibility: Inclusion Criteria: 1. Histologically confirmed, newly diagnosed primary or secondary glioblastoma multiforme. 2. Treatment plan includes 60 Gy of focal radiation administered in 30 fractions, concurrently with temozolomide…. Goal: This clinical trial is testing the safety and efficacy of NanO2TM administered via intravenous infusion in combination with standard radiation and chemotherapy. NanO2TM is being developed to increase the amount of oxygen delivered to tumors which is hoped to increase the effectiveness of radiation therapy. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; NuvOx LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1) is being studied. Conditions: Glioblastoma Multiforme • Eligibility: Inclusion Criteria: * Age ≥ 18 years * Willing and able to give written informed consent * Diagnosis of Glioblastoma, IDH WT as defined by the WHO 2021…. Goal: * To evaluate the safety and tolerability of escalating doses of ERAS-801 in study participants with recurrent glioblastoma multiforme (GBM). * To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-801. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Katmai Pharmaceuticals Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Physiological MRI for Precision Radiotherapy IDH-wildtype Glioblastoma is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: * Informed consent; * Adults (18 years or older); * diagnosed with IDH-wildtype glioblastoma, as confirmed by pathology including molecular analysis post resection/biopsy; * referred to…. Goal: After surgery, a key step in treatment of patients diagnosed with glioblastoma (high grade brain tumour) is radiotherapy. The ideal clinical target volume (CTV) for radiotherapy treatment planning includes all tumour cells remaining after surgery. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Erasmus Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM is being studied. Conditions: Glioblastoma Multiforme • Eligibility: \*Age Limits - 18 years or older outside of the US, 22 years or older within the US. Inclusion Criteria: 1. Histologically confirmed diagnosis of GBM according to…. Goal: To test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM patients, compared to radiation therapy and temozolomide alone. In both arms, Optune® and maintenance temozolomide are continued following radiation therapy. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; NovoCure Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab is being studied. Conditions: Glioblastoma, Glioblastoma Multiforme (GBM) • Eligibility: Inclusion Criteria: * \> 18 year of age * ECOG 0-2 * Able to provide informed consent for the study * Minimum of 1 month from completion of…. Goal: This trial is a single arm study for patients receiving bevacizumab for IDH-wildtype glioblastoma. Patients receiving bevacizumab (an anti-VEGF therapy) will receive PSMA scans to investigate the role of PSMA expression in glioblastoma and its relationship to VEGF expression. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Royal North Shore Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma is being studied. Conditions: Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Astrocytoma, Grade IV +3 • Eligibility: Inclusion Criteria: * Glioblastoma or gliosarcoma (recurrent or newly diagnosed). * Karnofsky Performance Status 60 or greater. * Phase 0: Candidate for clinically indicated re-resection or biopsy of…. Goal: This is a phase 0/1 dose-escalation trial to determine the maximum tolerated dose of Mycophenolate Mofetil (MMF) when administered with radiation, in patients with glioblastoma or gliosarcoma. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; University of Michigan Rogel Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Metabolic Therapy Program In Conjunction With Standard Treatment For Glioblastoma is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: 1. Age 18 years or greater. 2. Newly-diagnosed histologically-confirmed GBM. 3. ECOG Performance Status 0-2. 4. Planned for 6 weeks of standard chemoradiation for GBM. 5.…. Goal: Glioblastoma (GBM), a very aggressive brain tumour, is one of the most malignant of all cancers and is associated with a poor prognosis. The majority of GBM cells display damaged mitochondria (the "batteries" of cells), so they rely on an alternate method for producing energy called the Warburg Effect, which relies nearly exclusively on glucose (in contrast, normal cells can use other molecules, such as fatty acids and fat-derived ketones, for energy). Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Waikato Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Short Course Chemo-Radiation Therapy for Patients With Newly Diagnosed Glioblastoma is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: Each patient must meet all of the following inclusion criteria for study enrollment: * Age ≥18 with ability to provide written informed consent * Pathologically confirmed…. Goal: This is a prospective, randomized, open-label, exploratory trial of temozolomide-based chemo-radiotherapy which compares two widely used established radiation schedules with either 40 Gy in 15 fractions or 25 Gy in 5 fractions with concurrent temozolomide for both schedules in patients with glioblastoma. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; John Flickinger.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme is being studied. Conditions: Glioblastoma Multiforme, Adult • Eligibility: Patients will be eligible for the study if they meet all of the following inclusion criteria and none of the exclusion criteria. Inclusion criteria 1. Written informed consent…. Goal: This is an open-label, multicenter, randomized, parallel, 2-arm, efficacy and safety study. Patients with GBM after failure of standard first line therapy will be randomized in a 2:1 ratio to receive berubicin or lomustine for the evaluation of OS. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; CNS Pharmaceuticals, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: * Age ≥18 years of age. * Glioblastoma with definitive resection prior to enrollment, with residual radiographic contrast enhancing disease on the post-operative CT or MRI…. Goal: Patients with newly diagnosed glioblastoma will be consented following tumor resection then undergo leukapheresis for harvest of peripheral blood leukocytes for generation of dendritic cells. Subjects will then receive standard of care (planned 6 weeks) radiation therapy (RT) and concurrent temozolomide (TMZ) at a standard targeted dose of 75 mg/m2/day. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Annick Desjardins, MD.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma is being studied. Conditions: Pediatric Solid Tumor, Pediatric Lymphoma, Pediatric Brain Tumor +5 • Eligibility: Inclusion Criteria: All Patients * Previously confirmed (histologically or cytologically) pediatric solid tumor (e.g., neuroblastoma, sarcoma), lymphoma (including Hodgkin's lymphoma), or malignant brain tumors that are clinically or…. Goal: The study evaluates CLR 131 in children, adolescents, and young adults with relapsed or refractory malignant solid tumors and lymphoma and recurrent or refractory malignant brain tumors for which there are no standard treatment options with curative potential. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Cellectar Biosciences, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme is being studied. Conditions: Glioblastoma, Gliosarcoma • Eligibility: Inclusion Criteria: -Patients must have histologically confirmed diagnosis of a recurrent/progressive WHO grade IV malignant gliomas (glioblastoma multiforme and gliosarcoma) and meet the following inclusion criteria: 1. Age…. Goal: This phase II clinical trial studies how well ERC1671 plus Granulocyte-macrophage colony-stimulating factor (GM-CSF) plus Cyclophosphamide with Bevacizumab works compared to Placebo Injection plus Placebo Pill with Bevacizumab in treating patients with recurrent/progressive, bevacizumab naïve glioblastoma multiforme and gliosarcoma (World Health Organization (WHO) grade IV malignant gliomas, GBM). Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Epitopoietic Research Corporation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Newly Diagnosed Glioblastoma is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: * Understood and Signed an informed consent form., with good compliance * Age: 18-75 years old；.Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2；Life…. Goal: Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed Glioblastoma.Take PFS as the main evaluation index, the purpose is to evaluate its effectiveness Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Sun Yat-sen University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Evaluation of in Vitro Antitumor Activity of GD2 CAR-T Cells in Glioblastoma is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: * Male or female, adult (age ≥ 18 years) * WHO 0 to 2 * Patient with a diagnosis of histologically proven de novo glioblastoma with…. Goal: Glioblastoma is a brain tumor with a very poor prognosis, affecting around 2,400 new patients every year. Current treatments do not provide good control of the disease. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Central Hospital, Nancy, France.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma is being studied. Conditions: Glioblastoma Multiforme (GBM) • Eligibility: Inclusion Criteria: * Cohort 1: Histologically proven newly diagnosed glioblastoma multiforme (GBM) who will undergo standard of treatment with radiation therapy (RT) and temozolomide (TMZ). * Cohort 2:…. Goal: The purpose of this study is to evaluate whether new metabolic imaging will be useful to physicians and patients with glioblastoma for making treatment decisions and seeing how well various types of treatment work. The goal is to improve the way patient care is managed in the future. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Susan Chang.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Patient-derived Glioma Stem Cell Organoids is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: * MRI imaging suggestive for glioblastoma * \> 18 years of age Exclusion Criteria: * Karnofsky index \< 70 * Clotting disorders * Neurosurgical contraindications for…. Goal: Rationale: Glioblastoma (GM) is the most frequent incurable adult brain tumor with median survival of 15 months after diagnosis, despite extensive treatment with surgery, radiation therapy and chemotherapy. Tumor recurrence is inevitable after which life prolonging therapies are no longer available. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Maastricht Radiation Oncology.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients is being studied. Conditions: Glioblastoma Multiforme of Brain • Eligibility: Inclusion Criteria: * Newly diagnosed, histologically verified glioblastoma (WHO grade IV) * Aged ≥ 18 years * Total or subtotal resection: * Total resection: macroscopic complete resection as…. Goal: In this phase I/II trial, the primary objective is to determine overall and progression-free survival of patients with newly diagnosed glioblastoma when autologous Wilms' tumor 1 (WT1) messenger (m)RNA-loaded dendritic cell (DC) vaccination is added to adjuvant temozolomide maintenance treatment following (sub)total resection and temozolomide-based chemoradiation. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; University Hospital, Antwerp.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pembrolizumab in Treating Patients With Recurrent Glioblastoma is being studied. Conditions: Recurrent Glioblastoma, Recurrent Gliosarcoma • Eligibility: Inclusion Criteria: * Be willing and able to provide written informed consent/assent for the trial * Have histologically confirmed World Health Organization grade IV malignant glioma (glioblastoma or…. Goal: This phase II trial studies the effects of pembrolizumab on the body, or pharmacodynamics, in patients with glioblastoma that has come back. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study for Cerebral Open Flow Microperfusion is being studied. Conditions: Glioma, Glioblastoma • Eligibility: Inclusion Criteria * ECOG performance status (PS) 0, 1 or 2. * Clinical and radiographic evidence diagnosis of glioma, or a prior diagnosis of glioma (suspected WHO grade…. Goal: The purpose of this study is to evaluate the safety and feasibility of intra-operative microperfusion during a planned neurosurgical resection of diseased brain parenchyma, including either an epileptic focus requiring temporal lobectomy or a glioma. Devices used for microperfusion are Joanneum Research cerebral open flow microperfusion (OFM) catheters, push and pull tubing, and MPP102-II pump. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Mayo Clinic.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) is being studied. Conditions: Glioblastoma Multiforme of Brain • Eligibility: Inclusion Criteria: * Newly diagnosed MGMT unmethylated glioblastoma multiforme (no prior treatment) * Sufficient cancer tissue obtained to allow for manufacture of autologous cancer cell vaccines * The…. Goal: This randomized study is designed to compare the combination of TVI-Brain-1 immunotherapy and standard therapy compared to standard therapy alone as a treatment for newly diagnosed MGMT unmethylated glioblastoma patients. The patients' own cancer cells collected after surgery are combined into a vaccine to produce an immune response that significantly increases the number of cancer neoantigen-specific effector T cell precursors in the patient's body. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; TVAX Biomedical.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma is being studied. Conditions: Ependymoma, Glioblastoma, Medulloblastoma +1 • Eligibility: Inclusion Criteria: * Participant has verified leptomeningeal metastases * Participant must have a Karnofsky performance status (KPS) \>= 60 * Participant must have a life expectancy of \>=…. Goal: This phase I trial investigates the side effects of brain tumor-specific immune cells (IL13Ralpha2-CAR T cells) in treating patients with leptomeningeal disease from glioblastoma, ependymoma, or medulloblastoma. Immune cells are part of the immune system and help the body fight infections and other diseases. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; City of Hope Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Trial of Ipatasertib in Combination With Atezolizumab is being studied. Conditions: Solid Tumor, Glioblastoma Multiforme, Prostate Cancer Metastatic • Eligibility: Inclusion Criteria: 1. PART A1: Patients with histologically or cytologically confirmed malignant advanced solid tumours refractory to conventional treatment, or for which no conventional therapy exists or is…. Goal: This is a single centre, proof-of-concept phase I trial of atezolizumab in combination with ipatasertib. There are two parts to this study, the dose escalation phase (Part A) and the dose expansion phase (Part B). Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Institute of Cancer Research, United Kingdom.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Proof-of-Concept Study of ACT001 in Adult Patients With Recurrent Glioblastoma Harbouring STAT3-High Signature is being studied. Conditions: Recurrent Glioblastoma • Eligibility: Inclusion Criteria: * Histologically confirmed diagnosis of GBM according to 2021 WHO classification * Availability of tumor tissue representative of GBM from definitive surgery or biopsy and tested…. Goal: This trial will study the effectiveness of ACT001 in adult patients whose Glioblastoma have recurred with a STAT3-high signature after standard-of-care treatment with at least radiation therapy. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; National Neuroscience Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Immuno-Positron Emission Tomography (PET)-Glioma Study, a Proof-of-principle Imaging Study is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: * Patients with a new probable diagnosis of glioblastoma based on MRI imaging. * prior to initiation of specific tumor therapy and prior to any surgery…. Goal: Imaging of proinflammatory activated microglia by Purine 2X7 (P2X7) receptor scintigraphy in Positron Emission Tomography (PET) scanner in Glioblastoma patients. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Kepler University Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients is being studied. Conditions: Glioblastoma Multiforme, Meningioma • Eligibility: Inclusion Criteria * One prior resection of histologically-diagnosed World Health Organization (WHO) Grade III or IV glioma, or WHO grade II or III meningioma. * MRI evidence of…. Goal: In the proposed trial, patients will be administered ribociclib prior to surgical resection of their tumor. Patients will be enrolled in time-intervals sequentially (non-randomized). Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Nader Sanai.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Sonodynamic-Chemoradiotherapy Integration in Glioblastoma is being studied. Conditions: Glioblastoma (GBM) • Eligibility: Inclusion Criteria: 1. Signed informed consent form; 2. Age \< 75 years; 3. Newly diagnosed postoperative glioblastoma patients pathologically confirmed as glioblastoma; 4. Absence of severe hematopoietic dysfunction…. Goal: This Phase II trial tests if sonodynamic therapy (SDT)-a non-invasive treatment using ultrasound to activate a cancer-killing drug-improves outcomes for newly diagnosed glioblastoma patients. Who? Phase/Status/Sponsor: Unknown phase; ENROLLING_BY_INVITATION; Yingjuan Zheng.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery is being studied. Conditions: Glioblastoma Multiforme of Brain • Eligibility: Inclusion Criteria: 1. Age from 18 to 75 years (including 18 and 75 years old); 2. Newly-diagnosed glioblastoma confirmed by histopathological exams; 3. IDH1- and IDH2-wild-type gliomas; 4.…. Goal: This is a single-center, single-arm phase I study to determine the safety and preliminary efficacy of autologous dendritic cells (DCs) loaded with multiple tumor neoantigen peptides administered as a cancer-treatment vaccine to treat adult postoperative patients with newly-diagnosed glioblastoma, in combination with the standard-of-care Temozolomide (TMZ) chemotherapy. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Beijing Tiantan Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma is being studied. Conditions: High-grade Glioma, Oligodendroglioma, Astrocytoma +1 • Eligibility: Inclusion Criteria: 1. Confirmed recurrent gliomas that were originally diagnosed as high-grade glioma (World Health Organization \[WHO\] Grade 3 or 4; astrocytoma, oligodendroglioma, or glioblastoma) by histopathology or…. Goal: This is a phase 1 open-label, multicenter study to investigate tolerability, safety and PK properties of oral OKN-007 in patients with recurrent high-grade glioma. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Oblato, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: 1. Signed, written informed consent 2. Male or female age ≥ 18 years 3. Patients with glioblastoma, IDH-wildtype (as defined by WHO 2021 Classification of CNS…. Goal: This is an open-label phase 1 study to assess the safety and feasibility of autologous T cells co-expressing two CARs targeting the cryptic EGFR epitope 806 and IL13Ra2 (referred to as "CART-EGFR-IL13Ra2 cells") in patients with EGFR-amplified glioblastoma, IDH-wildtype that has recurred following prior radiotherapy. This study will take place in two parts: an initial dose escalation phase followed by a dose exploration phase. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; University of Pennsylvania.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria Dose Escalation Cohorts: 1. Written informed consent 2. Age ≥18 years 3. Patient agreement to diagnostic and scientific work-up of glioblastoma tissue obtained during the preceding…. Goal: The purpose of this study is to obtain first, exploratory information on the safety and efficacy of (i) olaptesed pegol in combination with radiation therapy in patients with newly diagnosed glioblastoma of unmethylated MGMT promoter status either not amenable to resection (biopsy only) or after incomplete tumor resection, and (ii) olaptesed pegol in combination with radiation therapy and bevacizumab in patients with newly diagnosed glioblastoma of unmethylated MGMT promoter status either not amenable to resection (biopsy only) or after incomplete or complete tumor resection. Further arms are included (i) to establish safety for the combination of olaptesed pegol at three different doses in addition to radiotherapy and bevacizumab, (ii) to explore the benefit of combining olaptesed pegol at different dose levels with bevacizumab in order to define the doses to move forward into a subsequent randomized dose-finding study, (iii) to explore the contribution of the therapy components olaptesed pegol and bevacizumab to patient benefit and (iv) to put the clinical outcome of these treatment regimens into perspective with the standard of care treatment with temozolomide and radiotherapy. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; TME Pharma AG.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This expanded access program provides ulixertinib (BVD-523) for compassionate use in people with advanced MAPK pathway–altered solid tumors (including KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations). It is for patients aged 12 and older who have exhausted or not adequately benefited from standard cancer therapies, and it may be given alone or with other tolerable drugs. The goal is to make ULIXERTINIB available and monitor safety and how well patients tolerate it in real-world use. Key exclusions include currently being enrolled in another ulixertinib trial, recent systemic therapy or radiotherapy within defined windows, history of retinal vein occlusion or central serous retinopathy, pregnancy or breastfeeding, significant uncontrolled illness, prior stomach/duodenal surgery affecting absorption, and use of certain interacting medications (strong inhibitors/inducers of CYP1A2, CYP2D6, or CYP3A4).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Personalized Radiation Therapy for GBM is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: * Patients with biopsy-proven WHO Grade IV glioblastoma, after gross-total or near-total resection, who are undergoing definitive chemoradiation as part of their treatment regimen * Age…. Goal: The study is a pilot study to estimate the efficacy of personalized dose-escalation radiation therapy in patients with glioblastoma, as measured by estimating the median of progression-free survival. Toxicity, patterns of recurrence, and overall median survival will be measured as secondary endpoints. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Abramson Cancer Center at Penn Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: * Biopsy proven, newly diagnosed, supratentorial, unifocal, lobar located IDH wild-type glioblastoma according to the criteria of the 2016 WHO classification. * Not safely and/or not…. Goal: The trial is an open, multicenter, explorative, pilot phase II study in a small number of patients to assess safety and efficacy of stereotactic interstitial photodynamic therapy (iPDT) with PD L 506 in newly diagnosed supratentorial IDH wild-type glioblastoma. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; photonamic GmbH & Co. KG.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Spatiotemporal Dimensions of Metabolism in Autochthonous Tumors of GBM Patients is being studied. Conditions: Glioblastoma Multiforme • Eligibility: Inclusion Criteria: 1. Preoperative MRI consistent with a primary intracranial malignant brain tumor. 2. Must be 18 years of age or older. 3. Patient eligible for debulking surgery/resection.…. Goal: To learn how altered metabolism in GBM causes tumor growth and resistance to drug therapy. In this pilot research study, we will dose GBM patients with a form of nicotinamide (a natural vitamin) that we can track. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; AdventHealth Translational Research Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy is being studied. Conditions: Recurrent Glioblastoma • Eligibility: Inclusion Criteria: * Must be between 18-80 years old * Histologically confirmed glioblastoma * Planned for Carboplatin monotherapy * Be willing and able to provided written informed consent/asent…. Goal: The purpose of this study is to evaluate the safety and feasibility of the Exablate Model 4000 Type 2 system when used as a tool to open the blood-brain-barrier (BBB) in subjects with recurrent glioblastoma (rGBM) undergoing carboplatin monotherapy. Phase/Status/Sponsor: Unknown phase; COMPLETED; InSightec.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

TVI-Brain-1 in Expanded Access Patient is being studied. Conditions: Recurrent Glioblastoma • Eligibility: Inclusion Criteria: Recurrent glioblastoma diagnosis confirmed * Age \> 18 * Informed consent * Diagnosis of grade IV glioma with progression following standard treatment. * Must be able…. Goal: TVI-Brain-1 is being offered as a potential treatment option to a Named Patient (Emergency Use Authorization IND) for recurrent glioblastoma as there is no effective systemic treatment available for this disease or patient. TVI-Brain-1 is an experimental treatment that takes advantage of the fact that your body can produce immune cells, called 'killer' white blood cells that have the ability to kill large numbers of the cancer cells that are present in your body. Phase/Status/Sponsor: Unknown phase; NO_LONGER_AVAILABLE; TVAX Biomedical.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Impact of the Platelet Level in Patients Treated for Glioblastoma With Temozolomid is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: * Age Superior to 18 years * Inform consent form signed * Newly diagnosed (histologically) glioblastoma * Stupp protocol treatment * with social insurance Exclusion Criteria:…. Goal: The purpose of GLIOPLAK is to evaluate the predictive value of a biological test performed in the radio-chemotherapy phase in patients suffering from glioblastoma. The studied parameter is the variation in platelet count during the radio-chemotherapy phase. Phase/Status/Sponsor: Unknown phase; COMPLETED; Centre Henri Becquerel.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: * Patients with histologically proven high grade glioma * Intention to start therapy Exclusion Criteria: * Severe psychiatric illness * Inability to give written consent *…. Goal: This pilot clinical trial studies fluordeoxyglucose (fludeoxyglucose) F-18 (FDG) positron emission tomography (PET)/computed tomography (CT) in monitoring very early therapy response in patients with glioblastoma. Diagnostic procedures, such as FDG PET/CT, may help measure a patient's response to earlier treatment. Phase/Status/Sponsor: Unknown phase; COMPLETED; Jonsson Comprehensive Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1) is being studied. Conditions: Recurrent Malignant Glioma, Glioblastoma Multiforme of Brain, Gliosarcoma of Brain +1 • Eligibility: Inclusion Criteria: Patients must have histologically or cytologically confirmed recurrent/progressive glioblastoma multiforme, anaplastic astrocytoma, or gliosarcoma. Prior therapy. Patients must have failed a course of external beam radiotherapy…. Goal: The purpose of this study is to determine how safe and how well-tolerated the experimental study drug, C134 is when re-administered into the brain where the tumor is located. Phase/Status/Sponsor: Unknown phase; TERMINATED; University of Alabama at Birmingham.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Clinical Trial to Assess the Efficacy and Safety of 'Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: 1. Patients who, prior to the study, received explanation of the purpose and content of study and of characteristics of the test drug from the test…. Goal: This clinical study was planned in order to assess the superiority of INNOCELL Corp. "Immuncell-LC" in aspects of therapeutic efficacy and safety when administered with Temozolomide to glioblastoma patients when compared with the control group who did not receive administration of the drug. Phase/Status/Sponsor: Unknown phase; COMPLETED; GC Cell Corporation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting is being studied. Conditions: Glioma, Glioblastoma, Glioblastoma Multiforme +2 • Eligibility: General Inclusion Criteria: * Patient must willingly provide written consent after being informed of the procedure to be followed, the experimental nature of the therapy, alternatives, potential benefits,…. Goal: The purpose of this phase 2, two arm, biomarker-driven study is to determine if treatment of O-6-methylguanine-DNA methyltransferase (MGMT) unmethylated glioblastoma with VAL-083 improves overall survival (OS), compared to historical control, in the adjuvant or recurrent setting. Phase/Status/Sponsor: Unknown phase; COMPLETED; Kintara Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing Ramipril to Prevent Memory Loss in People With Glioblastoma is being studied. Conditions: Glioblastoma, Radiotherapy; Complications, Cognitive Decline +1 • Eligibility: Inclusion Criteria: * Histologically proven diagnosis of glioblastoma or gliosarcoma (World Health Organization \[WHO\] grade IV) obtained at the time of a partial or gross total resection of…. Goal: This study is to determine if an oral drug called Ramipril can lower the chance of memory loss in patients with glioblastoma getting chemoradiation. Patients will take Ramipril during chemoradiation and continue until 4 months post-treatment. Phase/Status/Sponsor: Unknown phase; COMPLETED; Wake Forest University Health Sciences.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

FET-PET/MRI Based Treatment Planning for Glioblastoma Multiforme in Post-Surgical Patients (FET-TREAT) is being studied. Conditions: Glioblastoma Multiforme • Eligibility: Inclusion Criteria: Each participant must meet all of the following inclusion criteria to participate in this study: * ≥ 18 years of age * Diagnosis of glioblastoma multiforme…. Goal: Glioblastoma multiforme (GBM) represent the most common primary brain malignancy and prognosis remains poor. The most common subtype is glioblastoma which has a 5-year survival rate of approximately 5%. Phase/Status/Sponsor: Unknown phase; COMPLETED; Sunnybrook Health Sciences Centre.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients is being studied. Conditions: Glioblastoma, Squamous Cell Carcinoma, Hodgkin Lymphoma +14 • Eligibility: Inclusion Criteria: \- Exclusion Criteria: \-. Goal: AVM Biotechnology, Inc., provides immunomodulatory AVM0703 to solid tumor and blood cancer patients upon request by a US licensed MD or DO. As of July 2024, 37 patients have been treated through this FDA-EAP including patients diagnosed with relapsed or recurring glioblastoma, inoperable/chemotherapy ineligible CNS Squamous Cell Carcinoma, metastatic Breast Cancer, ovarian cancer, gastric cancer, Hodgkin's Lymphoma, Mixed Phenotype Acute Myelogenous Leukemia, colon cancer, B-ALL, Malignant Myxoid Spindle Cell Neoplasm, non-small cell lung cancer, DLBCL with CNS involvement, metastatic prostate cancer, Anaplastic T-cell Non-Hodgkin's Lymphoma and metastatic pancreatic cancer. Phase/Status/Sponsor: Unknown phase; AVAILABLE; AVM Biotechnology Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas is being studied. Conditions: Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain +1 • Eligibility: Inclusion Criteria: * Age ≥18 years * Evidence of primary or recurrent high-grade gliomas (HGG) that in the opinion of the treating team would require surgical resection *…. Goal: This research is being done to find out if the study drug (ketoconazole) can enter brain tumors at a high enough amount to stop the tumor cells from dividing. Ketoconazole is a drug which doctors already use for fungal infections and is thought to be able to effect tumor cells. Phase/Status/Sponsor: Unknown phase; TERMINATED; Milton S. Hershey Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter is being studied. Conditions: Glioblastoma, IDH-wildtype • Eligibility: Inclusion Criteria: * Written informed consent form signed and dated by patient or legally authorized representative according to local guidelines, prior to the performance of any study-specific procedures,…. Goal: This is a randomized, open-label, phase 2 study evaluating the safety and efficacy of oral ropidoxuridine as a radiation-sensitizing agent in patients with newly diagnosed wild-type isocitrate dehydrogenase glioblastoma with an unmethylated O6-methylguanine-DNA methyltransferase promoter, undergoing standard 60 Gy radiotherapy. Phase/Status/Sponsor: Unknown phase; TERMINATED; Shuttle Pharmaceuticals, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Longitudinal Assessment of Marrow and Blood in Patients With Glioblastoma is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: * Age ≥18 years of age. * Suspected newly-diagnosed GBM, World Health Organization (WHO) Grade IV with intent for gross total resection (as defined above). *…. Goal: The main goal of this study is to provide foundational data to drive translational approaches for an entirely novel category of immunotherapy. Phase/Status/Sponsor: Unknown phase; SUSPENDED; Duke University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma is being studied. Conditions: Glioblastoma, Gliosarcoma • Eligibility: Inclusion Criteria: * Signed informed consent form (ICF). * Ability and willingness to comply with the requirements of the study protocol. * Have histologically confirmed World Health Organization…. Goal: This phase I/II trial studies the side effects and how well atezolizumab works in combination with temozolomide and radiation therapy in treating patients with newly diagnosed glioblastoma. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Phase/Status/Sponsor: Unknown phase; COMPLETED; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab is being studied. Conditions: Glioblastoma, Glioblastoma Multiforme, Gliosarcoma +2 • Eligibility: * General Inclusion Criteria * Patients with histologically proven intracranial glioblastoma multiforme (GBM) or gliosarcoma (GS). Patients will be eligible if the original histology was low-grade glioma and…. Goal: Background: Glioblastoma is the most common and most aggressive type of malignant brain tumor. The drug pazopanib is used to treat people with a type of kidney cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors is being studied. Conditions: Advanced Solid Tumors, Glioblastoma, Soft Tissue Sarcoma (Excluding GIST) +9 • Eligibility: Inclusion Criteria: 1. Voluntarily signed and dated written informed consent prior to any specific-study procedure. 2. Age ≥ 18 years. 3. Eastern Cooperative Oncology Group (ECOG) performance status…. Goal: Prospective, open-label, dose-ranging, uncontrolled phase I/II study of Lurbinectedin in combination with irinotecan. The study will be divided into two stages: a Phase I dose escalation stage and a Phase II expansion stage. Phase/Status/Sponsor: Unknown phase; COMPLETED; PharmaMar.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Tryptophan Metabolism in Human Brain Tumors-Novocure is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: 1. Clinical and MRI diagnosis of recurrent GBM. 2. Age ≥22 years. 3. Patient agrees to NovoTTF treatment but has not started treatment yet. 4. Patient…. Goal: In this research study, we will track the build-up of tryptophan, a radioactive tracer, in the brain using positron emission tomography (PET) scanning. Tryptophan, in its natural state, is an amino acid (one of the building blocks of proteins) that is normally present in the brain, and is used by the brain cells to create various other compounds. Phase/Status/Sponsor: Unknown phase; COMPLETED; Wayne State University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma is being studied. Conditions: Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma +1 • Eligibility: Inclusion Criteria: * Patients with histologically confirmed glioblastoma or other grade IV malignant glioma (i.e. gliosarcoma, small cell glioblastoma, etc.), recurrent after prior external-beam fractionated radiotherapy and temozolomide…. Goal: NovoTTF-100A is a device and Bevacizumab is a study drug that have both been approved by the FDA (Food and Drug Administration) for use as monotherapy in treating glioblastoma multiforme. The NovoTTF-l00A is a portable battery operated device which produces TTFields within the human body using surface electrodes (transducer arrays). Phase/Status/Sponsor: Unknown phase; COMPLETED; Case Comprehensive Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas is being studied. Conditions: Glioma, Malignant • Eligibility: Inclusion Criteria: * Patients must have operable brain tumor presumed to be high grade glioma (HGG) based on clinical and radiologic evaluation, where a gross total surgical resection…. Goal: The purpose of this phase I trial is to test the safety of combining GMCI, an immunostimulator, plus nivolumab, an immune checkpoint inhibitor (ICI), with standard of care radiation therapy, and temozolomide in treating patients with newly diagnosed high-grade gliomas. Gene Mediated Cytotoxic Immunotherapy (GMCI) involves the use of aglatimagene besadenovec (AdV-tk) injection into the tumor site and oral valacyclovir to kill tumor cells and stimulate the immune system. Phase/Status/Sponsor: Unknown phase; COMPLETED; Candel Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma is being studied. Conditions: Brain and Central Nervous System Tumors • Eligibility: Key Inclusion Criteria: All participants 1. Age ≥ 18 years old. 2. Confirmed diagnosis of glioblastoma (WHO Grade IV). 3. Agreement to provide archival tumor tissue for exploratory…. Goal: The primary objective of this study is to evaluate the safety, efficacy and clinical activity of Pamiparib in combination with radiation therapy (RT) and/or temozolomide (TMZ) in participants with newly diagnosed or recurrent/refractory glioblastoma. Phase/Status/Sponsor: Unknown phase; COMPLETED; BeiGene USA, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Registry of Oncology Outcomes Associated with Testing and Treatment is being studied. Conditions: Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer +73 • Eligibility: Inclusion Criteria: * Patient or representative provides written informed consent * Patient is diagnosed with advanced malignancy * Patient is willing to be treated for this malignancy according…. Goal: This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation. Phase/Status/Sponsor: Unknown phase; COMPLETED; Taproot Health.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Brain Tumor Intraoperative Ultrasound Database is being studied. Conditions: Brain Tumor, Brain Neoplasms, Brain Cancer +2 • Eligibility: Inclusion Criteria: * Adult patients operated between January 2018 and January 2020 with a pathological diagnosis of WHO grade IV astrocytoma (Glioblastoma). * Intraoperative ultrasound study that includes…. Goal: Predicting the survival of patients diagnosed with glioblastoma (GBM) is essential to guide surgical strategy and subsequent adjuvant therapies. Intraoperative ultrasound (ioUS) is a low-cost, versatile technique available in most neurosurgical departments. Phase/Status/Sponsor: Unknown phase; COMPLETED; Hospital del Rio Hortega.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy Response in Glioblastoma is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: * Patients with histologically proven GBM * Newly diagnosed GBM. Prior surgery is allowed, but should not have started any other treatment such as chemotherapy, radiation…. Goal: MRI including ASL will be performed before, during and after the treatment, in a total of 7 MRI sessions until 8 months after the first session. Thereafter, patients will be followed through standard clinical examinations for the next 3 years or until demise, whichever occurs first. Phase/Status/Sponsor: Unknown phase; COMPLETED; University of Texas Southwestern Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Autologous Dendritic Cells, Metronomic Cyclophosphamide and Checkpoint Blockade in Children With Relapsed HGG is being studied. Conditions: Childhood Glioblastoma • Eligibility: Inclusion Criteria: 1. Diagnosis of relapsed high-grade malignant glioma confirmed by central neuropathological and neuroradiological review (last magnetic resonance imaging diagnosis not older than 4 weeks) - including…. Goal: This phase I/II trials evaluates the feasibility, safety and efficacy of an individualized cancer vaccine, based on autologous, tumor-lysate loaded dendritic cells in children and adolescents with relapsed high-grade gliomas. In addition, regulatory T cells are depleted by a short cycle of metronomic cyclophosphamide upfront of the vaccine in order to facilitate induction of immune responses. Phase/Status/Sponsor: Unknown phase; COMPLETED; Wuerzburg University Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma is being studied. Conditions: Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma • Eligibility: Inclusion Criteria: * Patients will have histologically proven intracranial glioblastoma multiforme (GBM) or gliosarcoma (GS); this includes treatment-naive patients with prior tissue diagnosis of lower grade gliomas that…. Goal: RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Phase/Status/Sponsor: Unknown phase; COMPLETED; Jonsson Comprehensive Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma is being studied. Conditions: Glioblastoma • Eligibility: INCLUSION CRITERIA: 1.1 Histologically confirmed World Health Organization (WHO) Grade IV glioblastoma. Patients with original histology of low-grade glioma and subsequent histological diagnosis of GBM are eligible. Other…. Goal: This research study is studying pembrolizumab and re-irradiation as possible treatments for glioblastoma. The drugs involved in this study are: * Pembrolizumab * Radiation * Bevacizumab, an FDA-approved drug for treating recurrent glioblastoma multiforme (GBM) Phase/Status/Sponsor: Unknown phase; COMPLETED; Dana-Farber Cancer Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial is being studied. Conditions: Primary Brain Tumor, Glioblastoma, Astrocytoma +3 • Eligibility: Inclusion Criteria: * Primary brain tumor diagnosis (grade I-IV) * \>/=2weeks post-cranial resection (if applicable) * \>/=1 month post-radiation therapy (if applicable) * Able to understand, speak, and…. Goal: This study seeks to investigate an evidence-based, manualized, behavioral health intervention, Cognitive Behavioral Therapy for Insomnia (CBT-I), in individuals with primary brain tumors (PBT) and insomnia. Our project will assess the feasibility and acceptability of recruitment, enrollment, data collection procedures, and retention of individuals with PBT and insomnia in the behavioral health intervention, CBT-I, and investigate the potential benefits of CBT-I within this at-risk and understudied population. Phase/Status/Sponsor: Unknown phase; COMPLETED; Virginia Commonwealth University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

18F-DOPA-PET/MRI Scan in Imaging Elderly Patients With Newly Diagnosed Grade IV Malignant Glioma or Glioblastoma During Planning for a Short Course of Proton Beam Radiation Therapy is being studied. Conditions: Glioblastoma, Malignant Glioma • Eligibility: Inclusion Criteria: * Histologically confirmed newly diagnosed grade IV malignant glioma * Planned radiation treatments at Mayo Clinic Arizona or Mayo Clinic Rochester * Willing to sign release…. Goal: This phase II trial studies how well fluorodopa F 18-positron emission tomography/magnetic resonance imaging scan (18F-DOPA-PET/MRI) works in imaging elderly patients with newly diagnosed grade IV malignant glioma or glioblastoma during planning for a short course of proton beam radiation therapy. 18F-DOPA is a chemical tracer that highlights certain cells during imaging. Phase/Status/Sponsor: Unknown phase; COMPLETED; Mayo Clinic.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Neoadjuvant Chemoradiation for Resectable Glioblastoma is being studied. Conditions: Glioblastoma, Surgery, High Grade Glioma • Eligibility: Inclusion Criteria: 1. Newly diagnosed GBM with histopathological confirmation. 2. Surgically suitable for subtotal or gross total resection as determined by central review. 3. Karnofsky Performance Status (KPS)\>70…. Goal: Preoperative therapy has not been well studied in resectable glioblastoma. This study attempts to prospectively assess the feasibility and efficacy of preoperative chemo radiation in improving local control, as this is the predominant mode of failure in these patients leading to poor outcomes. Phase/Status/Sponsor: Unknown phase; TERMINATED; Geisinger Clinic.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM is being studied. Conditions: Glioblastoma Multiforme, Glioblastoma, Glioma +2 • Eligibility: Inclusion Criteria: 1. Patient must agree to testing of GBM tumor promoter methylation status of the MGMT gene and tumor (IDH1) gene mutation status. Tissue may be tested…. Goal: This is an adaptive design, randomized controlled, Phase 3 clinical trial in patients with glioblastoma multiforme (GBM) or gliosarcoma (GS), previously treated with surgery (if appropriate), standard of care chemo-radiation with temozolomide, +/- adjuvant temozolomide, and bevacizumab and now has progressive disease during or after bevacizumab. A total of up to 180 eligible patients with recurrent/progressive GBM or GS will be randomized to receive either the investigational drug (VAL-083) or "Investigator's choice of salvage therapy" as a contemporaneous control, in a 2:1 fashion. Phase/Status/Sponsor: Unknown phase; TERMINATED; DelMar Pharmaceuticals, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Accurate DCE-MRI Measurement of Glioblastoma Using Point-of-care Portable Perfusion Phantom is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: 1. Adult patients (age 18 years or older). 2. Patients treated with surgery, followed by chemoradiation therapy, and currently under chemotherapy. 3. Patients with a newly…. Goal: The goal of this study is to test whether a new device developed at the University of Alabama at Birmingham (UAB) can decrease the error in calculating blood flow of a brain tumor, leading to better prognosis. UAB radiological research team has been studying a cutting-edge imaging technique named dynamic contrast enhanced (DCE) magnetic resonance imaging (MRI) , or DCE-MRI, over 10 years. Phase/Status/Sponsor: Unknown phase; COMPLETED; University of Alabama at Birmingham.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer is being studied. Conditions: Acute Myeloid Leukemia, Brain Glioblastoma, Estrogen Receptor Negative +64 • Eligibility: Inclusion Criteria: * Newly diagnosed patients for the following conditions * Colon cancer stage III and IV * Rectal cancer stage II, III, IV * Glioblastoma multiforme (brain)…. Goal: This randomized pilot clinical trial studies health care coach support in reducing acute care use and cost in patients with cancer. Health care coach support may help cancer patients to make decisions about their care that matches what is important to them with symptom management. Phase/Status/Sponsor: Unknown phase; COMPLETED; Stanford University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma is being studied. Conditions: Glioblastoma • Eligibility: Inclusion criteria * Inclusion criteria Part Phase 0: * Histologically (if prior biopsy) or radiologically diagnosed glioblastoma. * Neurosurgical tumor resection is indicated and planned according to the…. Goal: This study is open to adults with newly diagnosed glioblastoma, a type of brain tumor. The study has two parts. Phase/Status/Sponsor: Unknown phase; COMPLETED; Boehringer Ingelheim.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma is being studied. Conditions: Newly Diagnosed Glioblastoma • Eligibility: Inclusion Criteria: * Histologically confirmed newly diagnosed glioblastoma (WHO grade IV) * Tumor resection (gross total or partial), or biopsy only * Availability of formalin-fixed paraffin-embedded (FFPE) tumor…. Goal: The standard of care for newly diagnosed glioblastoma includes surgery, involved-field radiotherapy, and concomitant and six cycles of maintenance temozolomide chemotherapy, however the prognosis remains dismal. Marizomib has been tested in patients with newly diagnosed and recurrent glioblastoma in phase I and phase II studies. Phase/Status/Sponsor: Unknown phase; COMPLETED; European Organisation for Research and Treatment of Cancer - EORTC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System is being studied. Conditions: Central Nervous System Tumor • Eligibility: Inclusion Criteria: * MRI obtained within 30 days of study enrollment documents a measurable lesion consistent with a primary malignant central nervous system tumor for which maximal safe…. Goal: The purpose of this study is to examine the use of a single dose of tozuleristide (24 or 36 mg) and the Canvas imaging system during surgical resection of primary central nervous system (CNS) tumors: Primary gadolinium enhancing (high grade) CNS tumors, primary non-gadolinium enhancing CNS tumors, and primary vestibular schwannoma. The primary objectives of the study is to see how well tozuleristide and the Canvas imaging system during surgical resection will show fluorescence among primary enhancing/high grade CNS tumors; and among the tumors that demonstrate tozuleristide fluorescence, to estimate the true positive rate and true negative rate of fluorescence in tissue biopsies, as well as sensitivity and specificity of tozuleristide fluorescence for distinguishing tumor from non-tumoral tissue. Phase/Status/Sponsor: Unknown phase; COMPLETED; John Yu.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection is being studied. Conditions: Glioblastoma Multiforme, Glioma of Brain • Eligibility: Inclusion Criteria: 1. Prior resection of histologically-diagnosed WHO Grade III or IV glioma. A. Glioma patients who have progressed on or following standard (Stupp regimen) therapy, which included…. Goal: In the proposed trial, patients will be administered ribociclib+everolimus prior to surgical resection of their tumor. Recurrent GBM patients will be randomized into one of the three time-interval cohorts for the first two dose levels. Phase/Status/Sponsor: Unknown phase; COMPLETED; St. Joseph's Hospital and Medical Center, Phoenix.

This summary may be inaccurate. Verify against ClinicalTrials.gov.